Correlation of SpO₂/FiO₂ and PaO₂/FiO₂ in patients with symptomatic COVID-19: An observational, retrospective study

Aldo Bonaventura1 · Nicola Mumoli2 · Antonino Mazzone3 · Alessandra Colombo2 · Isabella Evangelista2 · Scilla Cerutti2 · Lorenzo Brivio3 · Alessandra Vecchiè1 · Alice Bonomi4 · Ombretta Para5 · Annamaria Bellizzi6 · Marco Ce7 · Patrizia Fenu7 · Flavio Tangianu1 · Francesco Dentali8 · Francesco Ce9

Received: 3 September 2021 / Accepted: 24 March 2022 / Published online: 23 April 2022
© The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2022

Abstract
Some patients affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience acute hypoxic respiratory failure progressing toward atypical acute respiratory distress syndrome (ARDS). The aim of the study is to evaluate whether a correlation between ratio of peripheral saturation of oxygen (SpO₂) and fraction of inspired oxygen (S/F) and ratio of arterial partial pressure of oxygen and fraction of inspired oxygen (P/F) exists in COVID-19-related ARDS as already known in classical ARDS. In this multicenter, retrospective, observational study, consecutive, adult (≥ 18 years) patients with symptomatic coronavirus disease 2019 (COVID-19) admitted to different COVID-19 divisions in Italy between March and December 2020 were included. Patients with SpO₂ > 97% or missing information were excluded. We included 1,028 patients (median age 72 years, prevalence of males [62.2%]). A positive correlation was found between P/F and S/F (r = 0.938, p < 0.0001). A receiver operating characteristic (ROC) curve analysis showed that S/F accurately recognizes the presence of ARDS (P/F ≤ 300 mmHg) in COVID-19 patients, with a cut-off of ≤ 433% showing good sensitivity and specificity. S/F was also tested against P/F values ≤ 200 and ≤ 100 mmHg (suggestive for moderate and severe ARDS, respectively), the latter showing great accuracy for S/F ≤ 178%. S/F was accurate in predicting ARDS for SpO₂ ≥ 92%. In conclusion, our findings support the routine use of S/F as a reliable surrogate of P/F in patients with COVID-19-related ARDS.

Keywords COVID-19 · SARS-CoV-2 · ARDS · Respiratory failure · Diagnosis · Cytokine storm

Abbreviations
ARDS Acute respiratory distress syndrome
AUC Area under the curve
CI Confidence interval
COVID-19 Coronavirus disease 2019
CPAP Continuous positive airway pressure
ICU Intensive care unit
IQR Interquartile range
LR Likelihood ratio
NIV Noninvasive ventilation
P/F Ratio between arterial partial pressure of oxygen and fraction of inspired oxygen
PaO₂ Arterial partial pressure of oxygen
ROC Receiver operating characteristic

Aldo Bonaventura and Nicola Mumoli equally contributed as first authors.

Aldo Bonaventura
aldo.bonaventura@asst-settelaghi.it

1 Medicina Generale 1, Medical Center, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy
2 Department of Internal Medicine, Magenta Hospital, ASST Ovest Milanese, Magenta, Italy
3 Department of Internal Medicine, Legnano Hospital, ASST Ovest Milanese, Legnano, Italy
4 Centro Cardiologico Monzino IRCCS, Milan, Italy
5 SOD Medicina Interna 1, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
6 Internal Medicine Unit, Frangipane Hospital, Ariano Irpino, Italy
7 Department of Internal Medicine, Cecina Hospital, Cecina, Italy
8 Department of Medicine and Surgery, Insubria University, Varese, Italy
9 Medicina Interna 1, Ospedale San Giuseppe, Empoli, Italy
Introduction

In a subset of patients, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for acute hypoxemic respiratory failure, that may progress toward acute respiratory distress syndrome (ARDS) [1, 2]. While most patients meet Berlin criteria for ARDS [3], a portion of them presents the so-called “happy” [4] or “silent hypoxemia” [5, 6] as they are not dyspnoic despite an abnormally low peripheral oxygen saturation. These patients display an atypical form of ARDS, characterized by a dissociation between a relatively preserved lung mechanics and severe hypoxemia, also referred to as early phenotype or L phenotype (lower elastance [high compliance], lower ventilation/perfusion ratio, lower lung weight, and lower recruitment) [7, 8]. Some of these patients may get worse and develop a phenotype closer to typical ARDS referred to as late phenotype or H phenotype, where high lung elastance [low compliance], high right-to-left shunt, high lung weight, and high recruitment are observed [7, 8].

Peripheral oxygen saturation (SpO2) is routinely used to estimate arterial oxygen saturation (SaO2) [9], but may be influenced by a number of factors, including peripheral perfusion [10]. A more precise estimation of arterial partial pressure of oxygen (PaO2) is obtained through arterial blood gas analysis that, however, requires a blood draw and is not feasible for long-term monitoring outside the intensive care unit (ICU). Changes in PaO2 present a good correlation with SpO2 variation in the range of 80–100% in healthy individuals [10–12]. The ratio between SpO2 and fraction of inspired oxygen (FiO2) (S/F) was found to well correlate with PaO2/FiO2 (P/F) in defining ARDS in adults [13, 14] and children [15] and to independently indicate short-term development of ARDS [16] and as a measure of hypoxia in patients under general anesthesia [17]. A recent paper emphasized the importance of S/F in predicting progression to severe illness or death in COVID-19 patients [18].

In an attempt to help clinicians involved in the care of patients with coronavirus disease 2019 (COVID-19), we sought to evaluate whether the correlation between S/F and P/F established for typical ARDS is confirmed also in COVID-19 symptomatic patients, irrespective of ARDS.

Materials and methods

Study design

This is a multicenter, retrospective, observational study including consecutive adult patients (≥ 18 years) with symptomatic COVID-19 confirmed by real-time polymerase chain reaction and admitted to COVID-19 divisions between March 1st and December 31st 2020. Participating centers were located in different Italian regions severely hit by both first and second wave of COVID-19: Lombardy (Varese, Legnano, and Magenta), Tuscany (Florence, Empoli, and Cecina), and Campania (Ariano Irpino). Patients with SpO2 > 97% were excluded from the analysis as the oxyhemoglobin dissociation curve plateaus above this level [19] (Fig. 1). As well, patients for whom data were missing were not considered for the analysis (Fig. 1). The exclusion of patients with SpO2 > 97% is based on findings by Van de Louw et al., who found that patients with an SpO2 > 94% had at least an SaO2 > 90% [20], which is considered as a clinical target in ICU patients receiving invasive mechanical ventilation [19]. It is then reasonable to assume that SpO2 > 97% depicts a sufficient oxygenation (in terms of SaO2). As ours was a non-ICU setting and invasive assessments were not available, we relied on pulse oximetry and patient clinical status to establish respiratory failure. For this reason, we feel that findings by Van de Louw et al. are reassuring about our decision to not consider patients with an SpO2 > 97%.

The research has been conducted in accordance with the Declaration of Helsinki (revised version 2000) and after approval of the local Institutional Review Board (Valutazione dell’efficacia di parametri clinici, laboratoristici e radiologici nella predizione dell’efficacia delle terapie in uso per il trattamento della sindrome da distress respiratorio acuta secondaria ad infezione da SARS-CoV-2 [REgistro COvid-19 asST setTE LAghi, RECOSTELA; number 150/2021]).

Data assessment

Arterial blood gas measurement was performed using RAPIDPoint® 500e Blood Gas System (Siemens Healthcare Srl, Milan, Italy) in Varese, Florence, and Ariano Irpino; GEM® 3500 PREMIER (Werfen, Instrumentation Laboratory S.p.A., Milan, Italy) in Cecina; ABL800 FLEX (A. De Mori S.p.A., Milan, Italy) in Magenta and Legnano; and ABL90 FLEX (Radiometer Medical ApS, Bronshøj, Copenhagen, Denmark) in Empoli. SpO2 was measured using the Pulse CO-Oximeter® Radical-7® (Masimo, Irvine, California, USA) in Varese, Florence.
and Ariano Irpino; Nellcor™ Portable SpO2 Patient Monitoring System, PM10N (Medtronic, Minneapolis, MN, USA) in Cecina and Empoli; and OXY-100 Pulsiossimeter (GIMA S.p.A., Gessate, Italy) in Magenta and Legnano. All measurements of SpO2, PaO2 and FiO2 were documented in patient medical records. Previously trained personnel, including nurses and doctors, assessed SpO2 values at the time of arterial blood gas sampling. When not feasible, the PaO2 assessment closest to the SpO2 value was recorded. To ensure accuracy of SpO2 assessments, the following considerations were followed: (1) no position changes 5 min prior to the measurement; (2) checking for the accurate position and cleanliness of the sensor; and (3) evaluation of satisfactory waveforms on the monitor. After 1 min of steady SpO2 measurement, the value was recorded along with the oxygen setting, i.e., room air or supplemental inspired oxygen (nasal cannula, Venturi mask, nonrebreather mask, continuous positive airway pressure [CPAP] or noninvasive ventilation [NIV]). FiO2 was estimated using a conversion table when oxygen was delivered via low-flow nasal cannula [21] and following manufacturer’s specifications when delivered via Venturi mask (Supplementary Table 1). For patients on non-rebreather mask, FiO2 was estimated using a 3%-formula (21% + oxygen flow rate in L/min × 3) [22, 23], that was found to have the best agreement and highest accuracy when compared with measured FiO2 [24]. Patients breathing on CPAP or noninvasive ventilation NIV had FiO2 recorded based on settings provided by the attending physician.

P/F < 300 mmHg was considered as a cut-off suggestive for ARDS, although not all patients were accurately screened for all Berlin criteria (bilateral opacities on chest imaging and respiratory failure not fully explained by cardiac failure or fluid overload) [3].

**Study endpoints**

The primary endpoint of the study was to evaluate whether a correlation between S/F and P/F exists in symptomatic COVID-19 patients admitted to Internal Medicine divisions, irrespective of ARDS occurrence.

The secondary endpoint was the evaluation of S/F as a reliable surrogate of P/F in defining ARDS based on P/F values defined by Berlin criteria [3].

**Statistical analysis**

Continuous variables that followed a non-normal distribution are presented as median and interquartile range [IQR]. Categorical variables are expressed as numbers and percentages (%). Ranked Spearman’s correlation coefficients were used to establish correlations between P/F and S/F. Plot calibration of the models assessing the goodness-of-fit of S/F to predict mild, moderate and severe ARDS was performed using the Hosmer–Lemeshow test. Receiver operating characteristic (ROC) curve analyses were performed to evaluate the accuracy of S/F to predict ARDS. The area under the curve (AUC) was given with 95% confidence interval (CI) and a cut-off point of S/F was also provided maximizing sensitivity and specificity in accordance with the Youden index. Positive and negative likelihood ratios (LRs) as well as positive and negative predictive values were also computed. Multiple ROC curve analyses were used to check for accuracy of S/F according to SpO2 strata and P/F cutoffs. A ROC curve analysis was finally run to test the prognostic
Table 1 Baseline characteristics

| Variables | Value |
|-----------|-------|
| Age, years | 72 [61–82] |
| Sex—female/male (%) | 389/639 (37.8/62.2) |
| SpO₂ (%) | 93.0 [90.0–95.0] |
| PaO₂/FiO₂, mmHg | 196.43 [115.57–285.71] |
| SpO₂/FiO₂ | 277.14 [178.0–433.33] |

PaO₂/FiO₂ ratio between arterial partial pressure of oxygen and fraction of inspired oxygen, SpO₂ peripheral oxygen saturation, SpO₂/FiO₂ ratio between peripheral oxygen saturation and fraction of inspired oxygen.

Accuracy of S/F in identifying ARDS according to the cut-off described by Rice et al. (i.e., < 315 mmHg) [13]. Plot calibration of the three ROC curves was performed using the Hosmer–Lemeshow test. A two-sided p < 0.05 value was considered as statistically significant. Statistical analyses were performed using IBM SPSS Statistics for Mac version 26.0 (IBM Co., Armonk, NY, USA), MedCalc 12.5 (MedCalc Software, Ostend, Belgium), and GraphPad Prism version 8.0.2 for Windows (GraphPad Software, San Diego, California USA, http://www.graphpad.com).

Results

Out the 1,497 patients consecutively considered, 1,028 were included in the present analysis (Fig. 1). Median age was 72 [61–82] years, with a prevalence of males (n = 639, 62.2%). At baseline, median P/F was 196.43 [115.57–285.71] mmHg, while median S/F was 277.14 [178.0–433.33] % (Table 1). A positive correlation was found between P/F and S/F in the overall cohort (r = 0.938, p < 0.0001; Fig. 2).

A ROC curve analysis showed that S/F accurately recognizes the presence of ARDS (as defined by P/F ≤ 300 mmHg [3]) in COVID-19 patients (AUC 0.958, p < 0.0001; Fig. 3A and Supplementary Table 2). The cut-off of S/F ≤ 433% was found to have the best sensitivity and specificity (94.6 and 86.2%, respectively; positive LR 6.85, negative LR 0.14). S/F was also tested against lower P/F values, i.e., ≤ 200 and ≤ 100 mmHg, suggesting moderate and severe ARDS, respectively. S/F highlighted moderate ARDS (as defined by P/F ≤ 200 mmHg [3]) with lower accuracy (AUC 0.713, 95% CI 0.944–0.969, p < 0.0001; Fig. 3B and Supplementary Table 2). Accordingly, the S/F cut-off ≤ 336% presented poor sensitivity and specificity as well as poor positive and negative LRs (Fig. 3B and Supplementary Table 2). Finally, a S/F cut-off ≤ 178% showed great accuracy in recognizing patients with severe ARDS (as defined by P/F ≤ 100 mmHg [3]), with good specificity and sensitivity (98.4% and 90.8%, respectively) and good positive and negative LRs (Fig. 3C and Supplementary Table 2). Calibration plots are provided in Supplementary Fig. 1.

We then observed that S/F was accurate in predicting ARDS for SpO₂ ≥ 92% (AUC > 0.900, p < 0.0001), while it failed for lower SpO₂ values (Table 2).

Finally, we confirmed that the S/F cut-off of < 315 mmHg, as found by Rice et al. [13], was accurate in diagnosing ARDS in patients with COVID-19 (AUC 0.826, 95% CI 0.802–0.849, p < 0.0001).

Discussion

In this study, we reported that S/F was very accurate in suggesting the occurrence of ARDS (P/F ≤ 300 mmHg, as defined by Berlin criteria [3]) for SpO₂ values ≥ 92%. This held true also when considering lower P/F values. In addition, we confirmed that S/F presented an excellent correlation with P/F also in COVID-19 patients.

COVID-19-related ARDS has some peculiar features [6], as previously mentioned. In the initial phase, a large portion of patients have a relatively good compliance in spite of a low oxygenation [8]. A subgroup of individuals progresses to a more aggressive disease with typical features of ARDS and usually referred to as having an H phenotype [8]. S/F was demonstrated to have a good correlation with P/F to detect patients with typical ARDS, either among adults [13, 14] and children [15]. S/F was also found to independently predict short-term development of ARDS [16]. S/F was found to be lower in non-survivor patients with ARDS compared with survivors and to be independently associated with death in the ICU [14] as well as with need for admission to the ICU [25].

Based on the abovementioned pathophysiological premises, we evaluated whether S/F held its accuracy in detecting patients with ARDS driven by SARS-CoV-2. The hypothesis stems from the easiness of using a non-invasive parameter...
to assess the degree of respiratory failure in patients with SARS-CoV-2-related pneumonia. This was an unmet clinical need in our medical divisions (i.e. Internal Medicine divisions) that coped with a large number of patients not needing ICU admission, whose patient management is different and not comparable. Indeed, we found that S/F has a positive, strong correlation with P/F in COVID-19 patients. We noticed that S/F is reliable in diagnosis ARDS for SpO2 values ≥ 92%, while it is not as accurate as for lower SpO2 values. From a practical standpoint, this information appears of great importance for those clinicians working outside the ICU setting. The reliability of SpO2 is known to be reduced for SpO2 < 90% [9]. When SpO2 falls below 90–92%, it is mandatory to have a blood gas analysis to carefully check for gas exchanges and modify therapeutic strategies accordingly. However, a simple tool like S/F may be a good surrogate of P/F to follow patients with respiratory failure due to SARS-CoV-2 pneumonia. This appears extremely important as P/F still represents an independent predictor of poor outcomes in COVID-19 patients [26, 27]. Differently from P/F, S/F does not need any blood draw and can be immediately available using a pulse oximeter both for outpatients and inpatients. The latter may represent an added value as S/F may be used as an accurate parameter to monitor patients with COVID-19 treated outside the hospital setting, who represented the majority of individuals affected by SARS-CoV-2 infection. As a further proof of this, we showed that S/F maintained a good accuracy in detecting patients with findings suggestive for different degrees of ARDS. By looking in more detail to our results, it looks like S/F may be used as a reliable surrogate for mild or severe ARDS (as per P/F values between 300 and 200 or ≤ 100 mmHg). On the contrary, for moderate ARDS, doubts still exist and blood gas analysis along with clinical evaluation appear the best tools for an escalating, therapeutic approach. This is in line with controversies recently arisen in the scientific community about this topic that certainly needs additional research in future [27, 28]. However, a recent study in COVID-19 patients strongly supports the reliability of S/F in predicting poor outcomes [18].

Our study has, however, some limitations that should be acknowledged. First, the retrospective design of the study conducted in a limited number of centers in Italy may limit the generalization of the results due to selection bias. However, patients were consecutively included in the study and recruited in regions hardly hit by SARS-CoV-2 pandemic,
thus giving a real picture of the disease severity. In addition, the sample is sufficiently large to ensure consistent results. Second, the large majority of patients were first admitted to the emergency department and then to a medical ward, so limited data are herein available about critically ill patients, who were mostly admitted to the ICU. Third, patients with SpO2 > 97% were excluded from analyses as for these values the slope of the relationship between SpO2 and PaO2 greatly plateaus. However, we do believe that this limitation may be acceptable as routine practice is based on FiO2 titration to reach and maintain SpO2 between 95 and 97% [29–31]. Fourth, we were not able to measure FiO2, except for Venturi mask (provided by manufacturer), NIV and CPAP. For other oxygen supports, FiO2 was estimated using the 3%-formula (21% + oxygen flow rate in L/min × 3), that was already tested in large trials [22, 23] and recognized to obtain the best agreement and highest accuracy compared with measured FiO2 [24]. Finally, although most of SpO2 and PaO2 measurements were assessed at the same time, separation by a few hours was tolerated and might have contributed to minimal differences between measurements. However, correlation between S/F and P/F remained very high.

In conclusion, our results support the routine use of S/F as a reliable surrogate of P/F in patients with COVID-19-related ARDS. This noninvasive and continuously available tool is helpful for an earlier diagnosis of ARDS and monitoring of respiratory function over time. S/F may also contribute to evaluating whether a step-up or step-down therapy is needed. From a patient’s perspective, routine use of S/F means less painful blood draws, that is important especially when hospital stay is prolonged. Future studies are warranted to evaluate whether this relationship between S/F and P/F holds true in the ICU setting.

**Table 2** ROC curve analyses for ARDS detection (P/F ≤ 300 mmHg) according to SpO2 strata

| SpO2 (%) | # of patients per group | AUC  | 95% CI            | p       |
|---------|-------------------------|------|-------------------|---------|
| 97      | 126                     | 0.958| 0.924–0.993       | <0.0001 |
| 96      | 102                     | 0.953| 0.909–0.957       | <0.0001 |
| 95      | 133                     | 0.939| 0.892–0.986       | <0.0001 |
| 94      | 104                     | 0.958| 0.919–0.998       | <0.0001 |
| 93      | 137                     | 0.951| 0.918–0.985       | <0.0001 |
| 92      | 87                      | 0.902| 0.838–0.965       | <0.0001 |
| 91      | 45                      | 0.534| 0.382–0.686       | 0.908   |
| 90      | 46                      | 0.642| 0.276–1.000       | 0.501   |
| <90     | 248                     | 0.764| 0.679–0.849       | 0.198   |

*AUC area under the curve, CI confidence interval, SpO2 peripheral oxygen saturation*

Acknowledgements We thank Lorenzo Caruso, Andrea Cozzi, Roberto Tarquini, Antea Milano, and Alessia Gilio for their precious help in collecting data.

**Author contributions** NM, AM, AC, IE, SC, LB, OP, AB, MC, PF, FT, and FC collected data. AB, NM, MC, and FC created the database. AB, AB, FD, and FC performed statistical analyses. AB drafted the first version of the manuscript. All authors critically reviewed the manuscript and provided suggestions. All authors approved the final version of the revised manuscript. AB and NM take responsibility for the integrity of the work as a whole. AB and NM equally contributed as first authors.

**Declarations**

**Conflict of interest** Aldo Bonaventura and Alessandra Vecchieti received a travel grant from Kiniksa Pharmaceuticals Ltd. to attend the 2019 AHA Scientific Sessions and honoraria from Effetti s.r.l. (Milan, Italy) to collaborate on the medical website http://www.inflammology.org not related to the present work. The other authors have nothing to disclose.

**Human And Animals Rights** The research has been conducted in accordance with the Declaration of Helsinki (revised version 2000) following approval of the local Institutional Review Board (Valutazione dell’efficacia di parametri clinici, laboratoristici e radiologici nella predizione dell’efficacia delle terapie in uso per il trattamento della sindrome da distress respiratorio acuta secondaria ad infezione da SARS-CoV-2 [Registro COVID-19 asST settE LAghi; RECOSTELA; number 150/2021].

**Informed Consent** Written informed consent was obtained from all study participants or their legal representatives.

**References**

1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324(8):782–793
2. Bonaventura A, Vecchie A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, Dentali F, Montecucco F, Massberg S, Levi M, Abbate A (2021) Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 21(5):319–329
3. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS (2012) Acute respiratory distress syndrome: the Berlin definition. JAMA 307(23):2526–2533
4. Couzin-Frankel J (2020) The mystery of the pandemic’s “happy hypoxia.” Science 368(6490):455–456
5. Xie J, Tong Z, Guan X, Du B, Qiu H, Slutsky AS (2020) Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med 46(5):837–840
6. Busana M, Gasperetti A, Giosa L, Forleo GB, Schiavone M, Mitacchione G, Bonino C, Villa P, Galli M, Tondo C, Saguner A, Steiger P, Curnis A, Dello Russo A, Pugliese F, Mancone M, Marini JJ, Gattinoni L (2021) Prevalence and outcome of silent hypoxemia in COVID-19. Minerva Anestesiol 87(3):325–333
7. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiurumello D (2020) COVID-19 does not lead to a “Typical” acute respiratory distress syndrome. Am J Respir Crit Care Med 201(10):1299–1300
1. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld KB, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Gervais V, de Lassence A, Girard P, Vincent JL, Payen D (2007) Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest 132(2):410–417

2. Fukuda Y, Tanaka A, Homma T, Kaneko K, Uno T, Fujiwara A, Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Chevalier S, Herblanc A, Fartoukh M, Constantin JM, Tonnellier JM, Pierrot M, Mathonnet A, Beduneau G, Deleage-Metreau C, Richard JC, Brochard L, Robert R, Group FS, Network R (2015) High-flow oxygen through nasal cannula in acute hypoxic respiratory failure. N Engl J Med 372(23):2185–2196

3. Coudroy R, Frat JP, Girault C, Thille AW (2020) Reliability of methods to estimate the fraction of inspired oxygen in patients with acute respiratory failure breathing through non-rebreather reservoir bag oxygen mask. Thorax 75(9):805–807

4. Tobin MJ, Laghi F (2021) Noninvasive strategies in COVID-19 patients: a feasibility study. BMC Emerg Med 18(1):17

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.